Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Morpholine SCHEMBL2029282 | 0.95 | MEN1 (0.55) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Morpholine SCHEMBL20580623 | 0.89 | MEN1 (0.61) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Morpholine SCHEMBL29071034 | 0.89 | MEN1 (0.61) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Morpholine SCHEMBL29377463 | 0.89 | MEN1 (0.61) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Morpholine SCHEMBL11120537 | 0.89 | MEN1 (0.61) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Morpholine SCHEMBL28817299 | 0.89 | MEN1 (0.61) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Morpholine SCHEMBL7727917 | 0.89 | MEN1 (0.61) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Morpholine SCHEMBL29208541 | 0.86 | MEN1 (0.58) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Morpholine SCHEMBL28503414 | 0.84 | MEN1 (0.55) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Morpholine SCHEMBL28056944 | 0.84 | MEN1 (0.55) | MEN1KMT2AKDM4EGAACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353421-B2 | Aptamers that are specific for immunoglobulin-binding cell wall proteins | Helmholtz-Zentrum für Umweltforschung GmbH-UFZ (DE) | 2016-05-31 | — | — | US | claimed |
| EP-3841218-B1 | NUCLEIC ACID BASED DETECTION METHODS | APTAMER DIAGNOSTICS LTD (GB) | 2024-06-26 | — | — | EP | disclosed |
| CN-117957022-A | Antisense compounds and methods for targeting CUG repeats | 安卓达治疗股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| US-11898146-B2 | Aptamers against Clostridium difficile, compositions comprising aptamers against Clostridium difficile and methods of using the same | LIV PROCESS, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| WO-2023141386-A1 | SYSTEM AND PROCESS FOR VISUALIZING TARGET MOLECULES | LIV PROCESS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| US-20230228751-A1 | APTAMERS AGAINST SARS-COV-2 | Aptamer Diagnostics Limited (GB) | 2023-07-20 | — | — | US | disclosed |
| CN-116438307-A | Aptamer against SARS-CoV-2 | 适体诊断有限公司 | 2023-07-14 | — | — | CN | disclosed |
| US-20230200397-A1 | METHODS OF REDUCING OR PREVENTING CLOSTRIDIOIDES DIFFICILE COLONIZATION | LIV PROCESS, INC. (US) | 2023-06-29 | — | — | US | disclosed |
| EP-4168551-A1 | APTAMERS AGAINST SARS-COV-2 | Aptamer Diagnostics Limited (GB) | 2023-04-26 | — | — | EP | disclosed |
| CN-115956122-A | Methods of reducing or preventing colonization by clostridium difficile | 利夫加工有限公司 | 2023-04-11 | — | — | CN | disclosed |
| WO-2007031333-A2 | IMPROVEMENTS IN OR RELATING TO AMPHOTERIC LIPOSOMES | NOVOSOM AG (DE) | 2007-03-22 | — | — | WO | disclosed |
| EP-1764089-A1 | Serum stable liposomes comprising amphoter II lipid mixtures | Novosom AG (DE) | 2007-03-21 | — | — | EP | disclosed |
| EP-1764090-A1 | Amphoteric liposomes for local drug applications | Novosom AG (DE) | 2007-03-21 | — | — | EP | disclosed |
| EP-1764091-A2 | Improvements in or relating to amphoteric liposomes | Novosom AG (DE) | 2007-03-21 | — | — | EP | disclosed |
| US-20060216343-A1 | Pharmaceutical compositions comprising an oligonucleotide as an active agent | NOVOSOM AG (DE) | 2006-09-28 | — | — | US | disclosed |
| US-20060159737-A1 | Pharmaceutical compositions for local administration | NOVOSOM AG (DE) | 2006-07-20 | — | — | US | disclosed |
| WO-2006063149-A1 | NUCLEOSIDES WITH ANTIVIRAL AND ANTICANCER ACTIVITY | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2006-06-15 | — | — | WO | disclosed |
| WO-2006053646-A2 | IMPROVEMENTS IN OR RELATING TO PHARMACEUTICAL COMPOSITIONS FOR LOCAL ADMINISTRATION | NOVOSOM AG (DE) | 2006-05-26 | — | — | WO | disclosed |
| EP-1658839-A1 | Oligonucleotide/carrier combinations targeting CD40 | Novosom AG (DE) | 2006-05-24 | — | — | EP | disclosed |
| WO-2006048329-A1 | IMPROVEMENTS IN OR RELATING TO PHARMACEUTICAL COMPOSITIONS COMPRISING AN OLIGONUCLEOTIDE AS AN ACTIVE AGENT | NOVOSOM AG (DE) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060159737-A1 | Pharmaceutical compositions for local administration | LIPA, GOT1, CHMP4B | MEN1 912/4885KMT2A 3860/4885KDM4E 3816/4885 |
| US-20060216343-A1 | Pharmaceutical compositions comprising an oligonucleotide as an active agent | CD40LG, CD40, TLR9 | MEN1 1090/4885KMT2A 3179/4885KDM4E 3675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.